Altamira Therapeutics annual return on equity
2022
2024
Altamira Therapeutics Return on Equity (ROE) Growth & History (CYTOF)
Altamira Therapeutics's return on equity was −118.79% for fiscal 2024.
View full Altamira Therapeutics company overviewAltamira Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −118.79% | — |
| 2022 | 2022-12-31 | −924.43% | — |
Altamira Therapeutics return on equity trends
Between the periods ended 2022-12-31 and 2024-12-31, Altamira Therapeutics's return on equity increased from −924.43% to −118.79%, a change of +805.65 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Altamira Therapeutics source filings ↗